arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Acumen Pharmaceuticals, Inc.

ABOS

$2.43 ▲ +0.15 (+6.35%) at close

7 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Acumen Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $147.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -105.4% ↘

FCF / Share $-1.91 ↘

Trailing P/E —

Price / Book 2.1x

FCF Yield —

Debt / Equity 0.44

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-121.33M

↓ -18.6% —

FCF / Share Free cash flow per share

$-1.91

↓ -32.8% —

Long-Term Debt Long-term obligations

$22.40M

↓ -23.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-17.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-58.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-1.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	78.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-18.6% Weak ↑ Weak Improving Year-over-year change in net income	-95.4% Weak ↑ Weak Improving Year-over-year change in net income	-22.2% Weak ↑ Weak Improving Year-over-year change in net income	57.4% Excellent Excellent Year-over-year change in net income	-1273.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-32.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	-62.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-2.3% Weak Weak Year-over-year change in free cash flow	3.3% Caution Caution Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.18x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-105.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	33.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-100.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-47.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-8.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-17.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-172.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1249%)	-56.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-19.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-231%)	-22.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-251%)	-44.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-398%)	39.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+163%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.44x Good ↑ Good Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-26%)	0.16x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-73%)	0.11x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-81%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—
Interest Coverage (x)	-42.18x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-38.35x Weak Weak Operating income divided by interest expense Optimal: > 5x	-105.23x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-22.83M	$-6.21M	$-36.99M	$-130.10M	—	$-43.78M	$-6.55M
Debt / EBITDA (x)	-0.25x Excellent → Excellent Stable Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.26x Excellent ↓ Excellent Declining Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.49x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-2.00	$-1.71	$-1.08	$-1.06	$-5.02	—	—
Free Cash Flow per Share (USD)	$-1.91	$-1.44	$-0.89	$-0.87	$-0.90	—	—
Book Value per Share (USD)	$1.16	$3.03	$4.61	$4.60	$5.56	$-44.36	—
Tangible Book Value per Share (USD)	$1.16	$3.03	$4.61	$4.60	$5.56	$-44.36	—
Basic Weighted Avg Shares (shares)	60.56M	60.01M	48.61M	40.60M	20.06M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$92.25M	$150.70M	$233.64M	$172.52M	$193.51M	—	—
LT Debt (USD)	$22.40M	$29.42M	$29.90M	$0.00	—	—	—
Total Equity (USD)	$70.43M	$181.82M	$266.97M	$188.78M	$225.18M	$-18.59M	$-11.42M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$58.00K	$63.00K	$61.00K	$32.00K	$4.00K	—	—
Net Income, GAAP (USD)	$-121.33M	$-102.33M	$-52.37M	$-42.86M	$-100.61M	$-7.33M	—
Operating Cash Flow (USD)	$-115.54M	$-86.22M	$-43.06M	$-35.15M	$-17.96M	$-7.45M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Acumen Pharmaceuticals, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ABOS with peers